The estimated Net Worth of Robert J. Spiegel is at least $318 mil dollars as of 3 August 2022. Robert Spiegel owns over 8,750 units of Geron stock worth over $75,714 and over the last 14 years he sold GERN stock worth over $115,009. In addition, he makes $126,912 as Independent Director at Geron.
Robert has made over 5 trades of the Geron stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 8,750 units of GERN stock worth $38,413 on 3 August 2022.
The largest trade he's ever made was exercising 175,000 units of Geron stock on 13 September 2018 worth over $516,250. On average, Robert trades about 2,153 units every 34 days since 2010. As of 3 August 2022 he still owns at least 17,247 units of Geron stock.
You can see the complete history of Robert Spiegel stock trades at the bottom of the page.
Dr. Robert J. Spiegel M.D. serves as Independent Director of the Company. Dr. Spiegel has served as a director of Geron since May 2010. Dr. Spiegel currently serves as an Associate Professor at the Weill Cornell Medical School, a Senior Advisor to Warburg Pincus, a private equity firm, and an Advisor to the Israel Biotech Fund, a venture investment fund. He is also a member of the board of directors of Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing targeted medicines for cancer and other proliferative diseases, since September 2018; and several privately-held biotechnology companies. He previously served as a director for Avior Computing Corporation, a privately-held governance risk and compliance process technology company, from October 2011 to November 2017; Talon Therapeutics, Inc., a biopharmaceutical company, from July 2010 to July 2013; Capstone Therapeutics Corp., a biotechnology company, from May 2010 to January 2012; Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, from January 2015 to January 2018; and PDS Biotechnology Corporation (formerly Edge Therapeutics, Inc.), a biotechnology company, from August 2013 to March 2019; the Cancer Institute of New Jersey from 1999 to 2009; and Cancer Care New Jersey from 1995 to 2011. From March 2011 to April 2016, Dr. Spiegel served as Chief Medical Officer of PTC Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing treatments for rare disorders. In 2009, after 26 years with the Schering-Plough Corporation (now Merck & Co.), a global healthcare company, Dr. Spiegel completed a fellowship in medical oncology at the National Cancer Institute, and from 1981 to 1999 he held academic positions at the National Cancer Institute and New York University Cancer Center. Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania.
As the Independent Director of Geron, the total compensation of Robert Spiegel at Geron is $126,912. There are 15 executives at Geron getting paid more, with John Scarlett having the highest compensation of $1,941,140.
Robert Spiegel is 70, he's been the Independent Director of Geron since 2010. There are 1 older and 16 younger executives at Geron. The oldest executive at Geron Corp. is Stephen N. Rosenfield, 71, who is the Exec. VP, Chief Legal Officer & Corp. Sec..
Robert's mailing address filed with the SEC is C/O GERON CORPORATION, 919 E. HILLSDALE BLVD, SUITE 250, FOSTER CITY, CA, 94404.
Over the last 21 years, insiders at Geron have traded over $2,393,273 worth of Geron stock and bought 340,678 units worth $567,384 . The most active insiders traders include John A Scarlett, Daniel Bradbury y Stephen Rosenfield. On average, Geron executives and independent directors trade stock every 93 days with the average trade being worth of $587,812. The most recent stock trade was executed by Andrew J Grethlein on 8 July 2024, trading 674,348 units of GERN stock currently worth $1,159,879.
we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.
Geron executives and other stock owners filed with the SEC include: